Milestones

1. Dr. Sergio Vañó has been included in the top 2% of the most cited scientists worldwide, according to a bibliometric analysis conducted by Stanford University.
2. Award of the competitive public project: "Molecular profile of the progression of subclinical atherosclerosis in patients with psoriasis: The AtheroProgrePso Study." Ref. PI25/02100, in the AES 2025 call, funded by the ISCIII and led by Drs. González-Cantero and Jaén. Project focused on the analysis of the proteomic profile in patients with psoriasis and its association with cardiovascular risk.
3. Gallego M, Botella LM, Mascaraque M, Nicolás J, Albiñana V, Abarca E, Gilaberte Y, González S, Juarranz Á, Carrasco E. N-acetylcysteine and raloxifene boost photodynamic therapy against cutaneous squamous cell carcinoma by decreasing TGFß1 secreted by cancer-associated fi broblasts. Int. J. Biol. Sci. 2025;21(7): 3164 - 3182. DOI:10.7150/ijbs.106642.
4. Pérez J, Berna E, Abbad C, Goni L, Vazquez Z, Neria F, Cova R, Naharro J, Ballester A, Pindado C, Monge D, Blauvelt A, Jaen P, Mehta N, Gelfand JM, Martinez MA, Gonzalez Á. Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial. JAMA Dermatol. 2025;161(12): 1215 - 1223. DOI:10.1001/jamadermatol.2025.3410. In 2025, the results of the MEDIPSO study were published, receiving national recognition and inclusion in the journal of the Madrid Medical Association.
5. The organization of the 3rd edition of "The Psoriasis Revolution Event," a social impact project developed by Dr. González Cantero, aims to provide people with psoriasis, healthcare professionals, and the general public with access to knowledge and the latest scientific developments related to this condition through clear, positive, and optimistic language.